SLC27A2 and neoplasm: To further explore the effects of targeting FATP2, mouse hepatic IRI with tumour recurrence models (the liver tumour cells were injected into the portal vein immediately after reperfusion) were established with four treatment groups: (1) normal liver, (2) fatty liver, (3) fatty liver + lipofermata, and (4) fatty liver + lipofermata + IL-1β recombinant protein.